Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising.
Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.
Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised
Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...